Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A term that refers to high grade B-cell lymphoma, not otherwise specified or high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Biomarker and diagnostic research for high grade B-cell lymphoma has been reported in the published literature.
84 clinical trials registered, 36 recruiting. Interventions under study include drug therapy, biologic therapy, procedural interventions, and other interventions. Pipeline includes 39 PHASE2, 39 PHASE1, 2 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05890352](https://clinicaltrials.gov/study/NCT05890352) |
Data assembled from 3 of 12 sources · Last updated Nov 2, 2026, 3:00 PM UTC
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment |
PHASE2 |
SWOG Cancer Research Network |
RECRUITING |
[NCT01371630](https://clinicaltrials.gov/study/NCT01371630) | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | PHASE1 | M.D. Anderson Cancer Center | RECRUITING |
[NCT06834373](https://clinicaltrials.gov/study/NCT06834373) | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | PHASE2 | Mayo Clinic | RECRUITING |
[NCT06536049](https://clinicaltrials.gov/study/NCT06536049) | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | PHASE1 | Yazeed Sawalha | RECRUITING |
[NCT05544019](https://clinicaltrials.gov/study/NCT05544019) | Study of SGR-1505 in Mature B-Cell Neoplasms | PHASE1 | Schrödinger, Inc. | RECRUITING |
178 publications have been identified in PubMed for high grade B-cell lymphoma. Research spans Case Report / Case Series (46%), Review / Meta-Analysis (12%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 81 | 46% |
Research summaries | 22 | 12% |
Disease patterns and progression | 21 | 12% |
Laboratory research | 16 | 9% |
Testing and diagnosis research | 15 | 8% |
Clinical study results | 12 | 7% |
New treatment approaches | 8 | 4% |
Other research | 3 | 2% |
Battistella E (2026). [PMID: 42192933](https://pubmed.ncbi.nlm.nih.gov/42192933/). *Cancers (Basel)*. [Case Report / Case Series]
Abdullah H (2026). [PMID: 41859584](https://pubmed.ncbi.nlm.nih.gov/41859584/). *Cureus*. [Case Report / Case Series]
Lyle A (2026). [PMID: 42267449](https://pubmed.ncbi.nlm.nih.gov/42267449/). *Int J Surg Pathol*. [Case Report / Case Series]
Agha MA (2026). [PMID: 41559810](https://pubmed.ncbi.nlm.nih.gov/41559810/). *J Med Case Rep*. [Case Report / Case Series]
Kawamura N (2026). [PMID: 41572088](https://pubmed.ncbi.nlm.nih.gov/41572088/). *CEN Case Rep*. [Case Report / Case Series]
Zhang H (2026). [PMID: 41494018](https://pubmed.ncbi.nlm.nih.gov/41494018/). *PLoS One*. [Epidemiology / Natural History]
de Smet MD (2026). [PMID: 41534870](https://pubmed.ncbi.nlm.nih.gov/41534870/). *Klin Monbl Augenheilkd*. [Clinical Trial Publication]
Kurz KS (2026). [PMID: 42138053](https://pubmed.ncbi.nlm.nih.gov/42138053/). *Am J Surg Pathol*. [Diagnostic / Biomarker]
Nada R (2026). [PMID: 42088612](https://pubmed.ncbi.nlm.nih.gov/42088612/). *Case Rep Oncol Med*. [Case Report / Case Series]
Yomogida D (2026). [PMID: 41632354](https://pubmed.ncbi.nlm.nih.gov/41632354/). *CEN Case Rep*. [Case Report / Case Series]
AI-curated news mentioning high grade B-cell lymphoma
Updated Oct 18, 2026
A recent study characterizes the morphological, immunophenotypical, and cytogenetic features of high-grade B-cell lymphoma associated with 11q aberration. This research provides insights that could inform future diagnostic and therapeutic strategies.